William Blair Assumes Xenon Pharmaceuticals (XENE) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts XENE Hot Sheet
Price: $36.19 -1.04%
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 66
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 66
Join SI Premium – FREE
William Blair analyst Myles Minter assumes coverage on Xenon Pharmaceuticals (NASDAQ: XENE) with a Outperform rating.
For an analyst ratings summary and ratings history on Xenon Pharmaceuticals click here. For more ratings news on Xenon Pharmaceuticals click here.
Shares of Xenon Pharmaceuticals closed at $37.59 yesterday.
You May Also Be Interested In
- Yorkville Ives Starts Zscaler (ZS) at Outperform
- Yorkville Ives Starts Willdan Group (WLDN) at Outperform
- Yorkville Ives Starts Walt Disney (DIS) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
